<DOC>
	<DOCNO>NCT02078284</DOCNO>
	<brief_summary>This study evaluate safety intravenous ( IV ) infusion dimethyl sulfoxide ( DMSO ) cryopreserved platelet ( CPP ) participants World Health Organization ( WHO ) Grade 2 bleed spite receive transfusion liquid store platelet ( LSP ) past 48 hour collect adverse event ( AEs ) evaluate coagulation-related parameter assess evidence thrombotic event CPP LSP transfusion .</brief_summary>
	<brief_title>Phase 1 Safety Study Dimethyl Sulfoxide Cryopreserved Platelets</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Dimethyl Sulfoxide</mesh_term>
	<criteria>Male female , least 18 year age . Ability comprehend study procedure sign informed consent . If premenopausal female , must negative serum pregnancy test , , child bear potential , must use acceptable method contraception . Diagnosed following : acute leukemia ( ALL AML ) , chronic leukemia ( CML , CLL , CMML , hairy cell leukemia ) , myelodysplasia , aplasia , hematopoietic nonhematopoietic solid tumor , therapy ( chemotherapy radiation ) induce bone marrow aplasia hypoplasia . Either autologous allogeneic bone marrow transplant peripheral cord blood stem cell recipient may enrol . WHO grade 2 great bleeding . LSP transfusion within previous 48 hour . Acute chronic DIC evidence Ddimer great 8 μg/mL fibrinogen le 100 mg ( 0.1 g ) /dL . Both criterion must meet . If data medical record fibrin degradation product ( FDPs ) , FDP must &lt; =40 μg/mL ( FDP &gt; 40 μg/mL indicative DIC ) . PT aPTT &gt; 1.3 time upper limit normal laboratory . History major operative procedure require general anesthesia past 2 week . History prior major unprovoked thrombotic event and/or know inherited disorder coagulation platelet function ( history ) ( include clot catheter , etc ) . A history diagnosis immune thrombocytopenia , thrombotic thrombocytopenic purpura , hemolytic uremic syndrome . Females breastfeed . Venoocclusive disease possible venoocclusive disease . Receiving active , inpatient treatment antiplatelet drug and/or full anticoagulation therapy . Note : heparin flush may give daily blood draw patient central line keep line patent . Subject previously enrol study receive study transfusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>platelet transfusion</keyword>
</DOC>